Skip to main content

Table 1 Tumor volumes of increased FET-uptake and of Gd-enhancement in MRI at baseline and at time of relapse

From: Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume

Pat. No Tumor volumes at baseline Tumor volumes at relapse
  FET-1 (ml) MRI-1 (ml) Intersect FET-1 ∩ MRI-1 (ml) Intersect FET-1 ∩ MRI-1 (% of FET-1) FET-2 (ml) MRI-2 (ml) Intersect FET-2 ∩ MRI-2 (ml) Intersect FET-2 ∩ MRI-2 (% of FET-2)
1 10.4 0.8 0.4 3.8 3.7 3.7 0.0 0
2 6.9 0.6 0.2 2.9 10.9 8.9 0.7 8.7
3 6.8 3.7 2.2 32.4 11.3 8.1 5.0 44.2
4 1.1 6.8 1.3 9.9 12.2 9.3 7.6 62.3
5 13.4 6.0 3.5 26.1 13.9 12.0 1.1 7.9
6 15.0 1.3 0.5 3.3 35.1 16.2 23.5 67.0
7 6.7 6.4 0.0 0.0 6.2 19.4 0.8 12.9
8 25.2 1.3 1.3 5.2 22.1 26.8 10.0 45.3
9 4.7 6.5 1.5 31.9 5.6 27.0 5.6 100
10 6.8 4.9 1.6 23.5 56.0 39.6 0.0 0.0
11 62.9 19.4 12.0 19.1 46.7 41.8 23.4 50.1
12 59.0 19.5 11.3 19.2 66.8 43.5 5.5 8.2
13 9.1 1.1 1.1 12.1 12.8 113.0 1.7 13.3
Mean 17.5 6.0 3.0 14.6 23.3 28.4 6.5 32.3
Median 9.1 4.9 1.3 12.1 12.8 19.4 5.0 13.3
SD 19.6 6.1 4.0 11.5 20.9 28.8 8.1 31.5
range 1.1–62.9 0.6–19.5 0–12 0–32.4 3.7–66.8 3.7–113 0–23.5 0-100.0
  1. FET-1: pathological FET-Volume in ml at baseline (post surgery)
  2. MRI-1: Gd-contrast-enhancement in ml at baseline (post surgery)
  3. FET-2: pathological FET-Volume in ml at the time of relapse
  4. MRI-1: Gd-contrast-enhancement in ml at the time of relapse